Research Funding

2017 AIMM Call for Proposals Released

LOI Deadline: January 26, 2018
Award:  $350,000

The AIMM Research Award is intended to support highly creative and conceptually innovative high-risk research with the potential to accelerate critical discoveries or major advancements that will significantly impact military health and medicine. AIMM initiative funding supports novel research concepts and other efforts that initiate or enhance potential game-changers that may not be supported by other funding mechanisms or core programs. Applications using synthetic or systems biology-based approaches are highly encouraged.

The anticipated direct costs budgeted for the entire period of performance for an FY17 AIMM Research Award will not exceed $350,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.

Funding for this award mechanism supports applied research. Applied research utilizes systematic studies to understand the means to meet a recognized and specific need. It is a systematic expansion and application of knowledge to develop useful materials, devices, and systems or methods. It may be oriented, ultimately, toward the design, development, and improvement of prototypes and new processes to meet general mission area requirements.  Applied research may translate promising basic research into solutions for broadly defined military needs, short of system development. Applied research may include hypothesis-testing and/or proof-of-concept studies as well as work that refines concepts and ideas into potential solutions with a view toward evaluating technical feasibility of emerging approaches, technologies, and promising new products.

Proposed research may involve human subjects, but clinical trials do not meet the intent of this award mechanism. A clinical trial is defined as a prospective accrual of patients (human subjects) in whom an intervention (e.g., device, drug, biologic, surgical procedure, rehabilitative modality, behavioral intervention, or other) is tested for a measurable outcome with respect to safety, effectiveness, and/or efficacy. This outcome represents a direct effect on the subject of that intervention or interaction.

Important aspects of the AIMM initiative are as follows:
• Impact: The proposed research is expected to make an important and original contribution to advancing solutions relevant to military health and medicine and
ultimately lead to improved outcomes for Service members, Veterans, or military beneficiaries.
• Innovation: Research deemed innovative may represent a new paradigm, challenge existing paradigms, look at existing problems from new perspectives, or exhibit other uniquely creative qualities. Research may be innovative in study concept, research methods or technology, or adaptations of existing methods or technologies. Research that represents an incremental advance on previously published work is not considered innovative.

Download the RFA

Caspar Wistar Fellows Program

Deadline: January 29, 2018
Download the RFA

The Caspar Wistar Fellows Program (Program) will recruit two exceptional post-doctoral fellows as independent investigators, creating a springboard for the Caspar Wistar Fellows (Fellows) to facilitate a subsequent faculty appointment and join the next generation of scientific leaders.

The Wistar Institute Vaccine & Immunotherapy Center and The Wistar Institute Cancer Center comprise a group of 35 exceptional faculty dedicated to fundamental and translational research in cancer biology, immunology, virology and genetics. Fellows will be provided their own research space, resources and support needed to run their own labs and pursue their own independent research agenda. Fellows will be appointed for a three-year term with the possibility of extending an additional one to two years.  Two Fellows will be recruited in 2018: one Fellow with a cancer focus that will join Wistar’s NCI-designated Cancer Center and one with a vaccine/immunology focus that will join Wistar’s Vaccine & Immunotherapy Center.

Program candidates must demonstrate intellectual drive and superior research credentials, a particularly creative and innovative research plan, strong communication skills, and the motivation and demonstrated capacity to conduct research with minimal supervision. Candidates whose work is based on biological principles, but incorporates concepts from diverse fields, are encouraged to apply. Candidates must hold a Ph.D., M.D., or equivalent degree. Candidates are expected to have a strong publication.

The search committees will be led by established Wistar faculty and program leaders who are ideally suited to recognize how well a prospective candidate fits within the overall Wistar mission, and its specific programs. Interested candidates should electronically submit a cover letter, curriculum vitae, a description of previous research (one page), a concise statement of research plans (up to two pages), reprints of four publications and the names of three references to the attention of Maria Colelli, Search Coordinator Caspar Wistar Fellows Program (colelli@wistar.org).   Please see our ads online in Nature and Science magazines. Applications will be evaluated by January 29, 2018.   Interviews will be held beginning in April 2018.

 

RFP for Therapeutic Development Opportunities for Neuroprotection and Neuroregeneration in Multiple Sclerosis

Deadline:  December 20, 2017

The National Multiple Sclerosis Society invests in promising research to drive breakthroughs that will stop MS, restore function and end MS forever. As part of its commitment to addressing the needs of individuals affected by MS, the Society invites proposals to establish research partnerships with Fast Forward, LLC to accelerate and support development of therapeutic strategies relevant to MS.

  • The National MS Society has released a Request for Proposals to fund drug development opportunities for therapies promoting neuroprotection and repair. New treatment strategies are needed to stop disease worsening by preventing neurodegeneration and reversing neuronal damage so that lost function can be restored. Although it is recognized that animal models of MS provide only limited insight into the pathophysiology of neurodegenerative process, studies to evaluate impact on demyelination, remyelination, neuroprotection, neural plasticity, and repair are considered appropriate for this RFP
    • Pre-Applications will be accepted starting November 8, 2017.
    • Final date for acceptance of pre-applications: December 6, 2017.
    • Full Proposals will be due no later than December 20, 2017.

Areas of high impact for this program include:
* Therapeutic approaches that directly promote remyelination and/or neuroprotection (including stimulation of endogenous repair and cell-based approaches)
* Proof of concept studies with repurposed FDA-approved therapies that have defensible intellectual property or strong commercial viability

Research areas supported by this program include, but are not limited to:
* Early-stage target validation
* Optimization of pre-clinical compounds
* PK/ADMET studies for valid compounds in development
* Imaging studies to measure target occupancy or target-related pharmacodynamic effects that could support a future clinical trial

Eligibility:
This RFP is open to global commercial organizations and not-for-profit research institutions collaborating with a commercial organization. Consistent with our goal to support research and development conducted with a high level of quality control typical of the pharmaceutical industry, proposals from not-for-profit institutions will be considered if a majority of the work is conducted at reputable Contract Research Organizations with appropriate expertise relevant to the proposal.

Read more about this opportunity and how to apply.